LTRN Stock Summary and Trading Ideas (Lantern Pharma | NASDAQ:LTRN)

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Lantern Pharma trades on the NASDAQ stock market under the symbol LTRN.

As of July 9, 2026, LTRN stock price climbed to $3.35 with 337,036 million shares trading.

LTRN has a beta of 3.99, meaning it tends to be more sensitive to market movements. LTRN has a correlation of 0.20 to the broad based SPY ETF.

LTRN has a market cap of $42.74 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, LTRN traded as high as $11.99 and as low as $1.11.

The top ETF exchange traded funds that LTRN belongs to (by Net Assets): VTI, VXF, MEDX, DFSU, DFAC.

LTRN has underperformed the market in the last year with a price return of -5.4% while the SPY ETF gained +22.4%. However, in the short term, LTRN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +72.7% vs +11.5% return in SPY. But in the last 2 weeks, LTRN shares have been beat by the market, returning -15.2% compared to an SPY return of +2.5%.

LTRN support price is $2.90 and resistance is $3.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LTRN shares will trade within this expected range on the day.